Introduction/Objectives: Controlled ovarian hyperstimulation (COH) in women undergoing in vitro fertilisation (IVF) involves daily administration of recombinant follicle-stimulating hormone (FSH; follitropin alfa) to stimulate follicular maturation. As follicles grow, they initially secrete inhibin-B [1], making inhibin‑B a sensitive biomarker of early ovarian response. Substantial inter‑individual variability exists in FSH pharmacokinetics, meaning optimising the number of […]
